DPCA2-2_issue_v2
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Diabetes and bone health<br />
“It is important,<br />
where possible, to<br />
ensure that messages<br />
from different<br />
clinicians pertaining<br />
to lifestyle factors are<br />
aligned and overlap as<br />
much as possible.”<br />
Conclusion<br />
Diabetes and osteoporosis are increasingly<br />
prevalent diseases. Diabetes is an important<br />
clinical risk factor for osteoporosis and fracture,<br />
and as clinicians it is important to remember this<br />
association when managing people with diabetes.<br />
Diabetes-related complications, hypoglycaemia<br />
and obesity could increase the risk of falls<br />
and fragility fracture. HbA 1c<br />
targets should be<br />
individualised taking into consideration age,<br />
frailty, diabetes complications and falls risk.<br />
While there is much to learn regarding the<br />
associations between diabetes, osteoporosis<br />
and fractures, it is important to recognise the<br />
value of performing a multifactorial fracture<br />
risk assessment, including falls risk. Tools are<br />
available to conveniently assess this risk and<br />
measurement of BMD by performing a DXA<br />
scan may provide additional useful information<br />
to help target those patients who are most<br />
at risk of fracture with appropriate fracture<br />
prevention drug therapies. The value of lifestyle<br />
modification to address fracture and falls risk<br />
cannot be underestimated. It is also convenient<br />
that the lifestyle modifications required to<br />
optimise bone health very much overlap with<br />
the lifestyle guidance that is offered to optimise<br />
the management of the underlying diabetes and<br />
obesity. It is important, where possible, to ensure<br />
that our messages to patients pertaining to<br />
lifestyle factors are aligned and overlap as much<br />
as possible, rather than conveying different sets<br />
of instructions for different disease areas. This<br />
is where diabetes and osteoporosis management<br />
from a self-help perspective very much align. n<br />
Acknowledgement<br />
This article has been modified from one<br />
previously published in Diabetes & Primary Care<br />
(2016, 2: 68–74).<br />
Anatomy & Physiology (2013) Age and Bone Mass. Wikimedia<br />
Commons. Available at: https://commons.wikimedia.org/wiki/<br />
File:615_Age_and_Bone_Mass.jpg (accessed 22.03.16)<br />
Blausen Medical Communications (2016) Osteoporosis locations.<br />
Wikimedia Commons. Available at: https://commons.wikimedia.org/<br />
wiki/File:Osteoporosis_Locations.png (accessed 22.03.16)<br />
Bonjour J-P, Chevalley T (2014) Endocr Rev 35: 820–47<br />
Botolin S, McCabe LR (2006) J Cell Physiol 209: 967–76<br />
Cundy TF et al (1985) Diabet Med 2: 461–4<br />
Dandona P, Dhindsa S (2011) J Clin Endocrinol Metab 96: 2643–51<br />
Food and Drug Administration (2015) FDA Drug Safety Communication.<br />
FDA, Silver Spring, MD, USA. Available at: www.fda.gov/Drugs/<br />
DrugSafety/ucm461449.htm (accessed 30.01.16)<br />
Gaillard F (2008) Brown tumours of the hands. Wikimedia Commons.<br />
Available at: https://commons.wikimedia.org/wiki/File:Brown_<br />
tumours_of_the_hands.jpg (accessed 22.03.16)<br />
Goh S-Y, Cooper ME (2008) J Clin Endocrinol Metab 93: 1143–52<br />
Gonnelli S et al (2014) Clin Interv Aging 9: 1629–36<br />
Handsaker JC et al (2014) Diabetes Care 37: 3047–53<br />
Hippisley-Cox J, Coupland C (2010) BMC Fam Pract 11: 1<br />
Hofbauer LC et al (2007) J Bone Miner Res 22: 1317–28<br />
Ivers RQ et al (2001) Diabetes Care 24: 1198–203<br />
Janghorbani M et al (2007) Am J Epidemiol 166: 495–505<br />
Kanazawa I et al (2011) Osteoporos Int 22: 1191–8<br />
Katayama Y et al (1996) J Bone Miner Res 11: 931–7<br />
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD<br />
Work Group (2009) Kidney Int Suppl 113: S1–130<br />
Kidney Health Australia (2015) Chronic Kidney Disease (CKD)<br />
Management in General Practice (3 rd edition). The Australian Kidney<br />
Foundation. Available at: http://bit.ly/2l8auNd (accessed 22.02.16)<br />
Magliano DJ, Peeters A, Vos T et al (2009) Aus NZ J Pub Health 33:<br />
540–3<br />
Mirza F, Canalis E (2015) Eur J Endocrinol 173: R131–51<br />
Monami M et al (2011) Diabetes Care 34: 2474–6<br />
Montagnani A, Gonnelli S (2013) Diabetes Obes Metab 15: 784–91<br />
National Osteoporosis Society (2013) Vitamin D and Bone Health.<br />
National Osteoporosis Society, Bath. Available at: https://www.nos.<br />
org.uk/document.doc?id=1352 (accessed 07.02.16)<br />
NICE (2009) Coeliac disease: recognition and assessment (CG86). NICE,<br />
London, UK<br />
NICE (2012) Osteoporosis: assessing the risk of fragility fracture (CG146).<br />
NICE, London, UK<br />
Pscherer S et al (2016) Diabetes Metab Syndr Obes 9: 17–23<br />
Rubin MR et al (2013) Expert Rev Endocrinol Metab 8: 423–5<br />
Schwartz AV et al (2008) Diabetes Care 31: 391–6<br />
Schwartz AV et al (2011) JAMA 305: 2184–92<br />
Shah VN et al (2015) Diabet Med 32: 1134–42<br />
Signorovitch JE et al (2013) Diabetes Obes Metab 15: 335–41<br />
Strotmeyer ES et al (2005) Arch Intern Med 165: 1612–7<br />
Su B et al (2015) Endocrine 48: 107–15<br />
Suzuki A et al (2006) Endocr J 53: 503–10<br />
Tahrani AA et al (2010) Int J Clin Pract 64: 351–5<br />
Vestergaard P (2007) Osteoporos Int 18: 427–44<br />
Vestergaard P et al (2005) Diabetologia 48: 1292–9<br />
Watts J, Abimanyi-Ochom, K, Sanders KM (2013) Osteoporosis<br />
is costing all Australian – a new burden of disease analysis –<br />
2012 to 2022. Osteoporosis Australia, Glebe. Available at:<br />
http://bit.ly/2lvhHI4 (accessed 22.02.16)<br />
Zhu Z-N et al (2014) Bone 68: 115–2<br />
68 Diabetes & Primary Care Australia Vol 2 No 2 2017